Laura Perez-Cano

Company: STALICLA

Job title: Head of Discovery

Seminars:

Clinical Translation of Precision Medicine in a First Clinically & Biologically Defined Subgroup of Patients with Autism Spectrum Disorder 9:30 am

A first clinically and biologically defined subgroup of ASD patients, named ASD-Phen1, was clinically validated in 2 prospectives biosampling studies with an observed incidence of 20-25% of the enrolled ASD population This subgroup was then biologically validated through multi-omics characterization revealing specific molecular signatures for ASD-Phen1 patients that were found to be reversed by STALICLA's…Read more

day: Conference Day 1 AM